Table 4. Outcomes: Bleeding and death in the two phases.

		Phase One N = 125	Phase Two N = 110	P–value*
Bleeding occurrence, n (%)
No		109 (87.2)	95 (86.4)
Yes		16 (12.8)	15 (13.6)	0.85
Bleeding sites**, n (%)
Digestive		8 (6.8)	13 (12.0)	0.18
Cerebral		7 (6.0)	0 (0.0)	0.02
Pulmonary		1 (0.9)	1 (1.0)	1.00
Bladder		0 (0.0)	1 (1.0)	0.47
Death
No		65 (52.0)	69 (62.7)
Yes		60 (48.0)	41 (37.3)	0.10
Death–Causes***, n (%)
Tumor		5 (7.1)	3 (4.2)	0.49
Heart failure		0 (0.0)	2 (2.8)	0.50
Septic shock		7 (9.7)	6 (8.0)	0.71
Cardiac arrest		34 (34.3)	27 (28.1)	0.35
Cerebral bleeding		6 (8.5)	0 (0.0)	0.01
Total bleeding		9 (12.2)	1 (1.4)	0.02
Stroke		3 (4.4)	0 (0.0)	0.12
All Cardiovascular Death	All sample	45 (40.9)	31 (31.0)	0.14
	On aspirin	13 (54.2)	4 (40.0)	0.45
	Not on aspirin	32 (37.2)	27 (30.0)	0.31

*Chi-square test, significant p-value < 0.05.

**The reference is those who did not bleed.

***The reference is those who did not die